Clinical and public genomic comparisons of carbapenem resistance in Pseudomonas aeruginosa
Frontiers in Microbiology · 05.11.2026 · 17
DOI: 10.3389/fmicb.2026.2002985 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 05.11.2026. Verfasst von Cheng-En Li und 7 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cross-setting comparisons of carbapenem resistance may reflect clinical contexts and selective genomic sampling. We examined reproducibility on two independent scales.
Methods
We analysed retrospective adult cohorts from a Chinese hospital ( n = 1,362) and the Medical Information Mart for Intensive Care IV (MIMIC-IV) v3.1 ( n = 3,251), along with 26,417 publicly submitted clinical Pseudomonas aeruginosa BioSamples. Our clinical analyses compared susceptibility-defined carbapenem-resistant Pseudomonas aeruginosa (CRPA), evaluated outcomes, adjusting for associations, and conducted exploratory reciprocal model transport. Our genomic analyses examined annotated determinants, submission-year patterns, single-nucleotide polymorphism (SNP) clusters, and co-resistance, including cluster-weighted sensitivity analyses.
Results
CRPA proportions were 36.9 and 9.3% in the two institutions. Unadjusted in-hospital mortality and post-index hospital stay were higher among patients with CRPA. Adjusted association directions agreed for 13 of 18 covariates. Transported models showed modest discrimination (area under the curves [AUCs], 0.641 and 0.619) and marked miscalibration (calibration slopes, 0.45 and 0.52). Among the included public Biosamples, 60.7% carried a defined carbapenem-associated determinant and 24.4% carried an acquired carbapenemase. Chinese submissions had higher serine-carbapenemase positivity, whereas US submissions had higher metallo-β-lactamase and chromosomal-determinant positivity. The country OR for bla KPC changed from 8.04 in the full sample to 1.59 in the cluster-assigned weighted analysis; the OR for acquired carbapenemase changed from 1.32 to 0.67.
Conclusion
Clinical associations may recur without supporting a reliable transported prediction. Genomic contrasts are sensitive to sampling and analysis population. These exploratory, unlinked findings neither establish causal effects nor estimate national prevalence; genomic results do not confirm phenotypic CRPA.
Zitieren
APA
Li, C., Shen, Y., Yi, R., Chen, W., Zhang, D., Miao, S., Zhang, Z., & Fan, Z. (2026). Clinical and public genomic comparisons of carbapenem resistance in Pseudomonas aeruginosa. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.2002985
Vancouver
Li C, Shen Y, Yi R, Chen W, Zhang D, Miao S, et al. Clinical and public genomic comparisons of carbapenem resistance in Pseudomonas aeruginosa. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.2002985
BibTeX
@article{Li2026,
author = {Li, Cheng-En and Shen, Ying-Ying and Yi, Ru-Qin and Chen, Wei and Zhang, Ding and Miao, Sheng-Hui and Zhang, Zhi-Rong and Fan, Zhao-Kun},
title = {Clinical and public genomic comparisons of carbapenem resistance in Pseudomonas aeruginosa},
journal = {Frontiers in Microbiology},
year = {2026},
volume = {17},
doi = {10.3389/fmicb.2026.2002985}
}
EUVIMED